S
Seema Singhal
Researcher at Northwestern University
Publications - 309
Citations - 19108
Seema Singhal is an academic researcher from Northwestern University. The author has contributed to research in topics: Transplantation & Multiple myeloma. The author has an hindex of 61, co-authored 309 publications receiving 18193 citations. Previous affiliations of Seema Singhal include Memorial Hospital of South Bend & Dana Corporation.
Papers
More filters
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
Antitumor activity of thalidomide in refractory multiple myeloma.
Seema Singhal,Jayesh Mehta,Raman Desikan,D Ayers,Paula K. Roberson,Paul Eddlemon,Nikhil C. Munshi,Elias Anaissie,Carla S. Wilson,Madhav V. Dhodapkar,J Zeddis,Bart Barlogie +11 more
TL;DR: Thalidomide can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy, and is active against advancedMyeloma.
Journal ArticleDOI
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial,Brendan M. Weiss,Saad Z. Usmani,Seema Singhal,Ajai Chari,Nizar J. Bahlis,Andrew Belch,Amrita Krishnan,Robert Vescio,Maria-Victoria Mateos,Amitabha Mazumder,Robert Z. Orlowski,Heather J. Sutherland,Joan Bladé,Emma C. Scott,Albert Oriol,Jesus G. Berdeja,Mecide Gharibo,Don A. Stevens,Richard Leblanc,Michael Sebag,Natalie S. Callander,Andrzej Jakubowiak,Darrell White,Javier de la Rubia,Paul G. Richardson,Steen Lisby,Huaibao Feng,Clarissa M. Uhlar,Imran Khan,Tahamtan Ahmadi,Peter M. Voorhees +31 more
TL;DR: Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in this population of patients.
Journal ArticleDOI
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Bart Barlogie,Sundar Jagannath,K. R. Desikan,S Mattox,David H. Vesole,David S. Siegel,Guido Tricot,Nikhil C. Munshi,A. Fassas,Seema Singhal,Jayesh Mehta,Elias Anaissie,D. Dhodapkar,S. Naucke,J. Cromer,Jeffery R. Sawyer,Joshua Epstein,D. Spoon,Dan Ayers,Bruce Cheson,John Crowley +20 more
TL;DR: Time-dependent covariate analysis suggested that timely application of a second transplant extended both EFS and OS significantly, independent of cytogenetics and beta-2-microglobulin.
Journal ArticleDOI
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib
Paul G. Richardson,Hannah R. Briemberg,Sundar Jagannath,Patrick Y. Wen,Bart Barlogie,James R. Berenson,Seema Singhal,David S. Siegel,David Irwin,Michael W. Schuster,Gordan Srkalovic,Raymond Alexanian,S. Vincent Rajkumar,Steven A. Limentani,Melissa Alsina,Robert Z. Orlowski,Kevin Najarian,Dixie Lee Esseltine,Kenneth C. Anderson,Anthony A. Amato +19 more
TL;DR: Bortezomib-associated peripheral neuropathy seemed reversible in the majority of patients after dose reduction or discontinuation, and the overall occurrence was independent of baseline neuropathy or type of prior therapy.